1. Home
  2. IMMX vs HGBL Comparison

IMMX vs HGBL Comparison

Compare IMMX & HGBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMX
  • HGBL
  • Stock Information
  • Founded
  • IMMX 2014
  • HGBL 1937
  • Country
  • IMMX United States
  • HGBL United States
  • Employees
  • IMMX N/A
  • HGBL N/A
  • Industry
  • IMMX Medicinal Chemicals and Botanical Products
  • HGBL Business Services
  • Sector
  • IMMX Health Care
  • HGBL Consumer Discretionary
  • Exchange
  • IMMX Nasdaq
  • HGBL Nasdaq
  • Market Cap
  • IMMX 65.5M
  • HGBL 66.7M
  • IPO Year
  • IMMX 2021
  • HGBL N/A
  • Fundamental
  • Price
  • IMMX $2.19
  • HGBL $1.95
  • Analyst Decision
  • IMMX Strong Buy
  • HGBL Strong Buy
  • Analyst Count
  • IMMX 1
  • HGBL 1
  • Target Price
  • IMMX $7.00
  • HGBL $4.00
  • AVG Volume (30 Days)
  • IMMX 250.2K
  • HGBL 42.6K
  • Earning Date
  • IMMX 08-08-2025
  • HGBL 08-07-2025
  • Dividend Yield
  • IMMX N/A
  • HGBL N/A
  • EPS Growth
  • IMMX N/A
  • HGBL N/A
  • EPS
  • IMMX N/A
  • HGBL 0.10
  • Revenue
  • IMMX N/A
  • HGBL $48,940,000.00
  • Revenue This Year
  • IMMX N/A
  • HGBL $12.65
  • Revenue Next Year
  • IMMX N/A
  • HGBL $5.68
  • P/E Ratio
  • IMMX N/A
  • HGBL $19.67
  • Revenue Growth
  • IMMX N/A
  • HGBL N/A
  • 52 Week Low
  • IMMX $1.26
  • HGBL $1.52
  • 52 Week High
  • IMMX $3.20
  • HGBL $2.39
  • Technical
  • Relative Strength Index (RSI)
  • IMMX 39.38
  • HGBL 41.31
  • Support Level
  • IMMX $2.11
  • HGBL $1.80
  • Resistance Level
  • IMMX $2.39
  • HGBL $1.98
  • Average True Range (ATR)
  • IMMX 0.21
  • HGBL 0.10
  • MACD
  • IMMX -0.03
  • HGBL -0.01
  • Stochastic Oscillator
  • IMMX 9.52
  • HGBL 37.50

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

About HGBL Heritage Global Inc.

Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.

Share on Social Networks: